Cogent Biosciences (COGT) Competitors $7.62 +0.21 (+2.77%) Closing price 07/3/2025 03:32 PM EasternExtended Trading$7.60 -0.02 (-0.20%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCMShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Its Competitors MoonLake Immunotherapeutics Metsera Viking Therapeutics Kymera Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech Immunovant Catalyst Pharmaceuticals HUTCHMED Cogent Biosciences (NASDAQ:COGT) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations. Which has better valuation & earnings, COGT or MLTX? MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$255.86M-$1.84-4.14MoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-20.16 Is COGT or MLTX more profitable? MoonLake Immunotherapeutics' return on equity of -30.81% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -149.79% -75.61% MoonLake Immunotherapeutics N/A -30.81%-28.40% Does the media prefer COGT or MLTX? In the previous week, Cogent Biosciences had 9 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 11 mentions for Cogent Biosciences and 2 mentions for MoonLake Immunotherapeutics. Cogent Biosciences' average media sentiment score of 0.90 beat MoonLake Immunotherapeutics' score of 0.82 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in COGT or MLTX? 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, COGT or MLTX? Cogent Biosciences has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Do analysts prefer COGT or MLTX? Cogent Biosciences currently has a consensus price target of $14.43, suggesting a potential upside of 89.48%. MoonLake Immunotherapeutics has a consensus price target of $74.50, suggesting a potential upside of 60.68%. Given Cogent Biosciences' higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCogent Biosciences and MoonLake Immunotherapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$863.03M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-4.147.9419.5920.21Price / SalesN/A281.76418.25119.02Price / CashN/A42.7336.8958.10Price / Book5.777.518.035.67Net Income-$255.86M-$55.14M$3.18B$249.21M7 Day Performance7.25%4.61%2.93%3.28%1 Month Performance27.13%4.72%3.75%5.55%1 Year Performance-9.77%5.92%35.20%21.09% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.5984 of 5 stars$7.62+2.8%$14.43+89.5%-8.9%$863.03MN/A-4.1480News CoverageAnalyst RevisionMLTXMoonLake Immunotherapeutics2.1639 of 5 stars$47.20-0.7%$74.50+57.8%+9.9%$3.04BN/A-20.522News CoveragePositive NewsMTSRMetseraN/A$28.45-0.5%$55.00+93.3%N/A$3.00BN/A0.0081VKTXViking Therapeutics4.3603 of 5 stars$26.50-0.1%$87.15+228.9%-44.2%$2.98BN/A-23.0420Trending NewsInsider TradeKYMRKymera Therapeutics3.1711 of 5 stars$43.64-1.1%$59.61+36.6%+48.6%$2.87B$47.07M-14.08170Analyst ForecastInsider TradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageCRNXCrinetics Pharmaceuticals3.3069 of 5 stars$28.76-4.0%$74.56+159.2%-32.4%$2.81B$1.04M-7.53210ALVOAlvotech3.5282 of 5 stars$9.12-0.2%$18.00+97.4%-24.4%$2.76B$491.98M24.651,032IMVTImmunovant1.4086 of 5 stars$16.00-0.6%$38.33+139.6%-35.9%$2.75BN/A-5.84120CPRXCatalyst Pharmaceuticals4.9181 of 5 stars$21.70-0.4%$32.83+51.3%+41.3%$2.66B$491.73M13.8280HCMHUTCHMED1.3545 of 5 stars$15.05-0.3%$19.00+26.2%-9.3%$2.63B$630.20M0.001,811Positive News Related Companies and Tools Related Companies MoonLake Immunotherapeutics Alternatives Metsera Alternatives Viking Therapeutics Alternatives Kymera Therapeutics Alternatives MorphoSys Alternatives Crinetics Pharmaceuticals Alternatives Alvotech Alternatives Immunovant Alternatives Catalyst Pharmaceuticals Alternatives HUTCHMED Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
